Jan. 22 (UPI) -- Paris-based pharmaceuticals maker Sanofi SA announced the acquisition of Bioverativ Inc. on Monday in a $11.6 billion offer.
Sanofi said it will pay $105 per share for the Massachusetts-headquartered Bioverativ, a 64 percent premium over Biovertiv's NASDAQ closing price of Friday. Bioverativ's stock value rose 62 percent in overnight trading on Monday.